209 related articles for article (PubMed ID: 1633906)
1. The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in in vitro fertilization: a prospective randomized study.
Tan SL; Balen A; el Hussein E; Campbell S; Jacobs HS
Fertil Steril; 1992 Aug; 58(2):378-83. PubMed ID: 1633906
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization.
Tan SL; Balen A; el Hussein E; Mills C; Campbell S; Yovich J; Jacobs HS
Fertil Steril; 1992 Jun; 57(6):1259-64. PubMed ID: 1601148
[TBL] [Abstract][Full Text] [Related]
3. Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome.
Isik AZ; Vicdan K
Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):208-12. PubMed ID: 11451550
[TBL] [Abstract][Full Text] [Related]
4. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
5. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction.
Blumenfeld Z; Lang N; Amit A; Kahana L; Yoffe N
Fertil Steril; 1994 Sep; 62(3):456-60. PubMed ID: 8062938
[TBL] [Abstract][Full Text] [Related]
6. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study.
Egbase PE; Sharhan MA; Grudzinskas JG
Hum Reprod; 1999 Jun; 14(6):1421-5. PubMed ID: 10357951
[TBL] [Abstract][Full Text] [Related]
7. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols.
Anaya Y; Mata DA; Letourneau J; Cakmak H; Cedars MI; Rosen MP
J Assist Reprod Genet; 2018 Feb; 35(2):297-307. PubMed ID: 29086322
[TBL] [Abstract][Full Text] [Related]
8. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
[TBL] [Abstract][Full Text] [Related]
9. The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study.
Younis JS; Simon A; Koren R; Dorembus D; Schenker JG; Laufer N
Fertil Steril; 1992 Sep; 58(3):575-80. PubMed ID: 1387849
[TBL] [Abstract][Full Text] [Related]
10. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
European Recombinant LH Study Group
J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
[TBL] [Abstract][Full Text] [Related]
11. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
12. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction.
Araujo E; Bernardini L; Frederick JL; Asch RH; Balmaceda JP
J Assist Reprod Genet; 1994 Feb; 11(2):74-8. PubMed ID: 7819706
[TBL] [Abstract][Full Text] [Related]
14. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
15. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
16. Serum and follicular fluid (FF) estradiol (E2) levels in ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) and gamete intrafallopian transfer (GIFT) conception cycles after pituitary suppression.
Leya J; Molo MW; Olson D; Radwanska E
J In Vitro Fert Embryo Transf; 1991 Jun; 8(3):137-40. PubMed ID: 1919258
[TBL] [Abstract][Full Text] [Related]
17. The effects of low-dose human chorionic gonadotropin combined with human menopausal gonadotropin protocol on women with hypogonadotropic hypogonadism undergoing ovarian stimulation for in vitro fertilization.
Jiang S; Kuang Y
Clin Endocrinol (Oxf); 2018 Jan; 88(1):77-87. PubMed ID: 28960429
[TBL] [Abstract][Full Text] [Related]
18. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
[TBL] [Abstract][Full Text] [Related]
20. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
